Results from IVANOS, a study evaluating Cerapedics’ i-FACTOR™ Peptide Enhanced Bone Graft in lumbar posterolateral spine surgery, demonstrated a 50% fusion rate in i-FACTOR patients vs. 20% fusion rate with allograft at one-year post-op.
The single-center, double-blind, randomized study treated 240 levels in 98 patients with lumbar spinal stenosis and accompanying degenerative olisthesis.
In the lumbar region, Cerapedics is also conducting an Investigational Device Exemption clinical trial of P-15L Peptide Enhanced Bone Graft vs. autograft in transforaminal lumbar interbody fusion to treat degenerative disc disease.
Sources: Cerapedics; ORTHOWORLD Inc.
Results from IVANOS, a study evaluating Cerapedics' i-FACTOR™ Peptide Enhanced Bone Graft in lumbar posterolateral spine surgery, demonstrated a 50% fusion rate in i-FACTOR patients vs. 20% fusion rate with allograft at one-year post-op.
The single-center, double-blind, randomized study treated 240 levels in 98 patients with lumbar spinal...
Results from IVANOS, a study evaluating Cerapedics’ i-FACTOR™ Peptide Enhanced Bone Graft in lumbar posterolateral spine surgery, demonstrated a 50% fusion rate in i-FACTOR patients vs. 20% fusion rate with allograft at one-year post-op.
The single-center, double-blind, randomized study treated 240 levels in 98 patients with lumbar spinal stenosis and accompanying degenerative olisthesis.
In the lumbar region, Cerapedics is also conducting an Investigational Device Exemption clinical trial of P-15L Peptide Enhanced Bone Graft vs. autograft in transforaminal lumbar interbody fusion to treat degenerative disc disease.
Sources: Cerapedics; ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.